XAGRID (anagrelide)


Xagrid is used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets circulating in the blood). ‘Essential’ means that the disease has no obvious cause. Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk’ because of their age (over 60 years), very high platelet counts or previous clotting problems.

Because the number of people with essential thrombocythaemia is low, the disease is considered ‘rare’, and Xagrid was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 29 December 2000.

Source: www.ema.europa.eu

Summary of the European Public Assessment Report (EPAR): 

Back to Catalogue of Drugs for Rare Diseases